{"id":744958,"date":"2014-06-30T05:00:00","date_gmt":"2014-06-30T05:00:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-investigational-anti-pd-1-antibody-pembrolizumab-under-regulatory-review-in-europe-for-the-treatment-of-advanced-melanoma\/"},"modified":"2023-03-22T00:04:53","modified_gmt":"2023-03-22T04:04:53","slug":"mercks-investigational-anti-pd-1-antibody-pembrolizumab-under-regulatory-review-in-europe-for-the-treatment-of-advanced-melanoma","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-investigational-anti-pd-1-antibody-pembrolizumab-under-regulatory-review-in-europe-for-the-treatment-of-advanced-melanoma\/","title":{"rendered":"Merck\u2019s Investigational Anti-PD-1 Antibody, Pembrolizumab, Under Regulatory Review in Europe for the Treatment of Advanced Melanoma"},"content":{"rendered":"<p>WHITEHOUSE STATION, N.J.&#8211;(<a target=\"_blank\" href=\"http:\/\/www.businesswire.com\" rel=\"noopener\">BUSINESS WIRE<\/a>)&#8211;Merck (NYSE:MRK), known as MSD outside the United States and Canada,<br \/>\n      today announced the European Medicines Agency (EMA) has accepted for<br \/>\n      review a Marketing Authorization Application (MAA) for pembrolizumab<br \/>\n      (MK-3475), the company\u2019s investigational anti-PD-1 antibody, for the<br \/>\n      treatment of advanced melanoma. If approved by the European Commission<br \/>\n      (EC), pembrolizumab has the potential to be the first anti-PD-1 therapy<br \/>\n      in Europe. Additional regulatory filings in other countries outside of<br \/>\n      Europe are planned by the end of 2014.\n    <\/p>\n<p>\n      \u201cWith the five-year survival rate for patients with advanced melanoma at<br \/>\n      less than 20 percent, there remains a need to offer patients additional<br \/>\n      options,\u201d said Dr. Roy Baynes, senior vice president, clinical<br \/>\n      development, Merck Research Laboratories. \u201cWe are pleased to have<br \/>\n      regulatory applications under review in the United States and Europe as<br \/>\n      we work toward bringing pembrolizumab to patients around the world.\u201d\n    <\/p>\n<p>\n      <b>About Advanced Melanoma<\/b>\n    <\/p>\n<p>\n      Melanoma is the most serious form of skin cancer and is the 19<sup>th<\/sup><br \/>\n      most common cause of cancer death in Europe. In 2012, there were an<br \/>\n      estimated 22,200 deaths from malignant melanoma in Europe. There were an<br \/>\n      estimated 232,000 new cases of melanoma diagnosed worldwide in 2012.\n    <\/p>\n<p>\n      <b>About Pembrolizumab<\/b>\n    <\/p>\n<p>\n      Pembrolizumab (MK-3475) is an investigational, selective, humanized,<br \/>\n      monoclonal anti-PD-1 antibody designed to reactivate anti-tumor<br \/>\n      immunity. Pembrolizumab exerts dual ligand blockade of the PD-1 pathway<br \/>\n      by inhibiting the interaction of PD-1 on T cells with its ligands PD-L1<br \/>\n      and PD-L2.\n    <\/p>\n<p>\n      Today, pembrolizumab is being evaluated across more than 30 types of<br \/>\n      cancers, as monotherapy and in combination. It is anticipated that by<br \/>\n      the end of 2014, the pembrolizumab development program will grow to more<br \/>\n      than 24 clinical trials, enrolling an estimated 6,000 patients at nearly<br \/>\n      300 clinical trial sites worldwide. For information about Merck\u2019s<br \/>\n      oncology clinical studies, please visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fclinical-trials%2Findex.html&#038;esheet=50896267&#038;newsitemid=20140630005326&#038;lan=en-US&#038;anchor=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fclinical-trials%2Findex.html&#038;index=1&#038;md5=2947d33d0b37e472c9a1fa52294a6dda\" rel=\"nofollow\">http:\/\/vip2-msd.com\/merckcom-migrated\/clinical-trials\/index.html<\/a>.\n    <\/p>\n<p>\n      The <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fwww.mercknewsroom.com%2Fnews-release%2Foncology-newsroom%2Fmerck-announces-fda-acceptance-review-mk-3475-biologics-license-appli&#038;esheet=50896267&#038;newsitemid=20140630005326&#038;lan=en-US&#038;anchor=Biologics+License+Application+%28BLA%29+for+pembrolizumab+is+under+priority+review&#038;index=2&#038;md5=2cc79230056bf74ea07a5bfcbd0ed2d4\" rel=\"nofollow\">Biologics<br \/>\n      License Application (BLA) for pembrolizumab is under priority review<\/a><br \/>\n      with the U.S. Food and Drug Administration (FDA) for the treatment of<br \/>\n      patients with advanced melanoma previously-treated with ipilimumab; the<br \/>\n      PDUFA date is October 28, 2014. Pembrolizumab has been granted FDA\u2019s<br \/>\n      Breakthrough Therapy designation for advanced melanoma. If approved by<br \/>\n      the FDA, pembrolizumab has the potential to be the first anti-PD-1<br \/>\n      therapy approved within the United States.\n    <\/p>\n<p>\n      <b>About Merck Oncology<\/b>\n    <\/p>\n<p>\n      At Merck Oncology, our goal is to translate breakthrough science into<br \/>\n      biomedical innovations to help people with cancer worldwide. Harnessing<br \/>\n      immune mechanisms to fight cancer is the priority focus of our oncology<br \/>\n      research and development program. The Company is advancing a pipeline of<br \/>\n      immunotherapy candidates and combination regimens. Cancer is one of the<br \/>\n      world&#8217;s most urgent unmet medical needs. Helping to empower people to<br \/>\n      fight cancer is our passion. For information about Merck\u2019s commitment to<br \/>\n      Oncology visit the Oncology Information Center at <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fwww.mercknewsroom.com%2Foncology-infocenter&#038;esheet=50896267&#038;newsitemid=20140630005326&#038;lan=en-US&#038;anchor=http%3A%2F%2Fwww.mercknewsroom.com%2Foncology-infocenter&#038;index=3&#038;md5=ebd1cd42dec4aabd53e8c0576f020201\" rel=\"nofollow\">http:\/\/www.mercknewsroom.com\/oncology-infocenter<\/a>.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      Today&#8217;s Merck is a global healthcare leader working to help the world be<br \/>\n      well. Merck is known as MSD outside the United States and Canada.<br \/>\n      Through our prescription medicines, vaccines, biologic therapies, and<br \/>\n      consumer care and animal health products, we work with customers and<br \/>\n      operate in more than 140 countries to deliver innovative health<br \/>\n      solutions. We also demonstrate our commitment to increasing access to<br \/>\n      healthcare through far-reaching policies, programs and partnerships. For<br \/>\n      more information, visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2F&#038;esheet=50896267&#038;newsitemid=20140630005326&#038;lan=en-US&#038;anchor=vip2-msd.com\/merckcom-migrated&#038;index=4&#038;md5=30d9d0222fa7f49338d4a5ce5ae05e4b\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and connect with us on <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=https%3A%2F%2Ftwitter.com%2Fmerck&#038;esheet=50896267&#038;newsitemid=20140630005326&#038;lan=en-US&#038;anchor=Twitter&#038;index=5&#038;md5=5dd4b004ce10302e40eb68f8a852de5d\" rel=\"nofollow\">Twitter<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fwww.facebook.com%2Fmerckbewell&#038;esheet=50896267&#038;newsitemid=20140630005326&#038;lan=en-US&#038;anchor=Facebook&#038;index=6&#038;md5=c30cbfd90762e52413bcde984edde6ec\" rel=\"nofollow\">Facebook<\/a><br \/>\n      and <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fwww.youtube.com%2Fmerck&#038;esheet=50896267&#038;newsitemid=20140630005326&#038;lan=en-US&#038;anchor=YouTube&#038;index=7&#038;md5=711b91d98a11675146e2e58af0ced523\" rel=\"nofollow\">YouTube<\/a>.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement<\/b>\n    <\/p>\n<p>\n      This news release includes \u201cforward-looking statements\u201d within the<br \/>\n      meaning of the safe harbor provisions of the United States Private<br \/>\n      Securities Litigation Reform Act of 1995. These statements are based<br \/>\n      upon the current beliefs and expectations of Merck\u2019s management and are<br \/>\n      subject to significant risks and uncertainties. There can be no<br \/>\n      guarantees with respect to pipeline products that the products will<br \/>\n      receive the necessary regulatory approvals or that they will prove to be<br \/>\n      commercially successful. If underlying assumptions prove inaccurate or<br \/>\n      risks or uncertainties materialize, actual results may differ materially<br \/>\n      from those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include, but are not limited to, general<br \/>\n      industry conditions and competition; general economic factors, including<br \/>\n      interest rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and healthcare legislation in the<br \/>\n      United States and internationally; global trends toward healthcare cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; Merck\u2019s ability to accurately<br \/>\n      predict future market conditions; manufacturing difficulties or delays;<br \/>\n      financial instability of international economies and sovereign risk;<br \/>\n      dependence on the effectiveness of Merck\u2019s patents and other protections<br \/>\n      for innovative products; and the exposure to litigation, including<br \/>\n      patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      Merck undertakes no obligation to publicly update any forward-looking<br \/>\n      statement, whether as a result of new information, future events or<br \/>\n      otherwise. Additional factors that could cause results to differ<br \/>\n      materially from those described in the forward-looking statements can be<br \/>\n      found in Merck\u2019s 2013 Annual Report on Form 10-K and the company\u2019s other<br \/>\n      filings with the Securities and Exchange Commission (SEC) available at<br \/>\n      the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fwww.sec.gov&#038;esheet=50896267&#038;newsitemid=20140630005326&#038;lan=en-US&#038;anchor=www.sec.gov&#038;index=8&#038;md5=a8bd94e9a756f03da8675967fd4bd1bf\" rel=\"nofollow\">www.sec.gov<\/a>).\n    <\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"\/\/cts.businesswire.com\/ct\/CT?id=bwnews&#038;sty=20140630005326r1&#038;sid=hq1sf1&#038;distro=nx&#038;lang=en\" \/><span class=\"bwct31415\"\/><\/span><\/p>\n<p>       Media:<br \/>Steve Cragle, 973-432-4781<br \/>Claire Mulhear, 908-423-7425<br \/>or<br \/>Investors:<br \/>Joseph        Romanelli, 908-423-5185<br \/>Justin Holko, 908-423-5088     <\/p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the European Medicines Agency (EMA) has accepted for review a Marketing Authorization Application (MAA) for pembrolizumab (MK-3475), the company\u2019s investigational anti-PD-1 antibody, for the treatment of advanced melanoma. If approved by the European Commission (EC), pembrolizumab has the potential to be the first anti-PD-1 therapy in Europe. Additional regulatory filings in other countries outside of Europe are planned by the end of 2014. \u201cWith the five-year survival rate for patients with advanced melanoma at less than 20 percent, there remains a need to offer patients additional options,\u201d said Dr. Roy Baynes, senior vice president, clinical development, Merck Research Laboratories. \u201cWe are pleased to have regulatory applications under review in the United States and Europe as we work toward bringing pembrolizumab to patients around the world.\u201d About Advanced Melanoma Melanoma is the most serious<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[137,138,289,56],"class_list":["post-744958","news_item","type-news_item","status-publish","hentry","tag-oncology","tag-oncology-newsroom","tag-press-release","tag-research-and-development-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Merck\u2019s Investigational Anti-PD-1 Antibody, Pembrolizumab, Under Regulatory Review in Europe for the Treatment of Advanced Melanoma - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-investigational-anti-pd-1-antibody-pembrolizumab-under-regulatory-review-in-europe-for-the-treatment-of-advanced-melanoma\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck\u2019s Investigational Anti-PD-1 Antibody, Pembrolizumab, Under Regulatory Review in Europe for the Treatment of Advanced Melanoma - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the European Medicines Agency (EMA) has accepted for review a Marketing Authorization Application (MAA) for pembrolizumab (MK-3475), the company\u2019s investigational anti-PD-1 antibody, for the treatment of advanced melanoma. If approved by the European Commission (EC), pembrolizumab has the potential to be the first anti-PD-1 therapy in Europe. Additional regulatory filings in other countries outside of Europe are planned by the end of 2014. \u201cWith the five-year survival rate for patients with advanced melanoma at less than 20 percent, there remains a need to offer patients additional options,\u201d said Dr. Roy Baynes, senior vice president, clinical development, Merck Research Laboratories. \u201cWe are pleased to have regulatory applications under review in the United States and Europe as we work toward bringing pembrolizumab to patients around the world.\u201d About Advanced Melanoma Melanoma is the most serious\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-investigational-anti-pd-1-antibody-pembrolizumab-under-regulatory-review-in-europe-for-the-treatment-of-advanced-melanoma\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2023-03-22T04:04:53+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png\" \/>\n\t<meta property=\"og:image:width\" content=\"3056\" \/>\n\t<meta property=\"og:image:height\" content=\"1380\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/mercks-investigational-anti-pd-1-antibody-pembrolizumab-under-regulatory-review-in-europe-for-the-treatment-of-advanced-melanoma\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/mercks-investigational-anti-pd-1-antibody-pembrolizumab-under-regulatory-review-in-europe-for-the-treatment-of-advanced-melanoma\\\/\",\"name\":\"Merck\u2019s Investigational Anti-PD-1 Antibody, Pembrolizumab, Under Regulatory Review in Europe for the Treatment of Advanced Melanoma - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"datePublished\":\"2014-06-30T05:00:00+00:00\",\"dateModified\":\"2023-03-22T04:04:53+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/mercks-investigational-anti-pd-1-antibody-pembrolizumab-under-regulatory-review-in-europe-for-the-treatment-of-advanced-melanoma\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/mercks-investigational-anti-pd-1-antibody-pembrolizumab-under-regulatory-review-in-europe-for-the-treatment-of-advanced-melanoma\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/mercks-investigational-anti-pd-1-antibody-pembrolizumab-under-regulatory-review-in-europe-for-the-treatment-of-advanced-melanoma\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck\u2019s Investigational Anti-PD-1 Antibody, Pembrolizumab, Under Regulatory Review in Europe for the Treatment of Advanced Melanoma\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Merck\u2019s Investigational Anti-PD-1 Antibody, Pembrolizumab, Under Regulatory Review in Europe for the Treatment of Advanced Melanoma - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-investigational-anti-pd-1-antibody-pembrolizumab-under-regulatory-review-in-europe-for-the-treatment-of-advanced-melanoma\/","og_locale":"en_US","og_type":"article","og_title":"Merck\u2019s Investigational Anti-PD-1 Antibody, Pembrolizumab, Under Regulatory Review in Europe for the Treatment of Advanced Melanoma - Merck.com","og_description":"Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the European Medicines Agency (EMA) has accepted for review a Marketing Authorization Application (MAA) for pembrolizumab (MK-3475), the company\u2019s investigational anti-PD-1 antibody, for the treatment of advanced melanoma. If approved by the European Commission (EC), pembrolizumab has the potential to be the first anti-PD-1 therapy in Europe. Additional regulatory filings in other countries outside of Europe are planned by the end of 2014. \u201cWith the five-year survival rate for patients with advanced melanoma at less than 20 percent, there remains a need to offer patients additional options,\u201d said Dr. Roy Baynes, senior vice president, clinical development, Merck Research Laboratories. \u201cWe are pleased to have regulatory applications under review in the United States and Europe as we work toward bringing pembrolizumab to patients around the world.\u201d About Advanced Melanoma Melanoma is the most serious","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-investigational-anti-pd-1-antibody-pembrolizumab-under-regulatory-review-in-europe-for-the-treatment-of-advanced-melanoma\/","og_site_name":"Merck.com","article_modified_time":"2023-03-22T04:04:53+00:00","og_image":[{"width":3056,"height":1380,"url":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-investigational-anti-pd-1-antibody-pembrolizumab-under-regulatory-review-in-europe-for-the-treatment-of-advanced-melanoma\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-investigational-anti-pd-1-antibody-pembrolizumab-under-regulatory-review-in-europe-for-the-treatment-of-advanced-melanoma\/","name":"Merck\u2019s Investigational Anti-PD-1 Antibody, Pembrolizumab, Under Regulatory Review in Europe for the Treatment of Advanced Melanoma - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"datePublished":"2014-06-30T05:00:00+00:00","dateModified":"2023-03-22T04:04:53+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-investigational-anti-pd-1-antibody-pembrolizumab-under-regulatory-review-in-europe-for-the-treatment-of-advanced-melanoma\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-investigational-anti-pd-1-antibody-pembrolizumab-under-regulatory-review-in-europe-for-the-treatment-of-advanced-melanoma\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-investigational-anti-pd-1-antibody-pembrolizumab-under-regulatory-review-in-europe-for-the-treatment-of-advanced-melanoma\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Merck\u2019s Investigational Anti-PD-1 Antibody, Pembrolizumab, Under Regulatory Review in Europe for the Treatment of Advanced Melanoma"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"4b33cf19-338f-4501-93d1-ad6334c8d7f6","news_item_aria_label":"","media_files":null,"document_path":"","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/744958","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":0,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/744958\/revisions"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=744958"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=744958"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}